Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

High rate of hypoglycemia in diabetic pregnant women on use of glyburide

Authors: Giordanna De Bacco, Vanessa Krebs Genro, Cristiano Caetano Salazer, Maria Lúcia R Opperman

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

The prevalence of gestational diabetes (GD) in Brazil can exceed 18% when applied the current WHO diagnostic criteria. The importance of the GD treatment in reducing severe outcomes of perinatal maternal morbidity and has been shown in randomized clinical trials. Therapeutic options for the GD have included oral antidiabetic agents glibenclamide (GB) and metformin (MF) showed Results of safety and efficacy similar to insulin. …
Metadata
Title
High rate of hypoglycemia in diabetic pregnant women on use of glyburide
Authors
Giordanna De Bacco
Vanessa Krebs Genro
Cristiano Caetano Salazer
Maria Lúcia R Opperman
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A85

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine